Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Economic sustainability and the emergence of infectious diseases remain critical challenges in tilapia aquaculture. Lactic acid bacteria (LAB) are well-known feed additives with probiotic effects in improving overall performance of livestock. This study evaluated the effects of host-associated probiotic, Leuconostoc lactis TARicum AI2, on growth performance, antioxidant, immune responses, and gut microbiota of red hybrid tilapia (Oreochromis sp.) by conducting an 86-day feeding trial. The probiotic, previously characterised for its beneficial traits, was coated on commercial feed at a concentration of 10 CFU g. Results showed tilapia fed with probiotic had significant improvement in feed conversion ratio (FCR) and protein efficiency ratio (PER) compared to the control group. Upregulation of cytokine expressions was observed in the probiotic group. Gut microbiota analysis revealed an increased abundance of the genera Clostridium and Leuconostoc in the probiotic-fed tilapia. Beta-diversity indices proved exclusive groups of bacteria present in specific diet only. In conclusion, L. lactis strain TARicum AI2 is a potential probiotic candidate in promoting growth in tilapia as the results suggested it could improve FCR and PER. Feed with lower FCR and higher PER could help tilapia farmers in reducing feed cost, which accounted for the major portion of their production cost. This further enables them to achieve cost-effective, enhanced productivity and economic sustainability in a long run.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00284-025-04137-wDOI Listing

Publication Analysis

Top Keywords

gut microbiota
12
microbiota red
8
red hybrid
8
hybrid tilapia
8
tilapia oreochromis
8
leuconostoc lactis
8
economic sustainability
8
taricum ai2
8
tilapia
7
feed
6

Similar Publications

EVOLVING TRENDS AND EMERGING THEMES IN GUT MICROBIOTA RESEARCH: A COMPREHENSIVE BIBLIOMETRIC ANALYSIS (2015-2024).

Arq Gastroenterol

September 2025

The Japanese Society of Internal Medicine, Editorial Department, Tokyo, Japan.

Background: This study aims to analyze research trends and emerging insights into gut microbiota studies from 2015 to 2024 through bibliometric analysis techniques. By examining bibliographic data from the Web of Science (WoS) Core Collection, it seeks to identify key research topics, evolving themes, and significant shifts in gut microbiota research. The study employs co-occurrence analysis, principal component analysis (PCA), and burst detection analysis to uncover latent patterns and the development trajectory of this rapidly expanding field.

View Article and Find Full Text PDF

Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAID.

J Crohns Colitis

September 2025

Department of Gastroenterology, University Hospital of Marseille Nord, Assistance Publique-Hôpitaux de Marseille (AP-HM), Aix-Marseille University, Marseille, France.

Background And Aims: While this strategy is frequently used for other biologics, real-world evidence on subcutaneous (SC) vedolizumab (VDZ) dose intensification in inflammatory bowel disease (IBD) is lacking. This study aimed to assess the effectiveness and safety of SC VDZ intensification.

Methods: We conducted a retrospective study in 25 centers including all patients with active ulcerative colitis (UC) or Crohn's disease (CD) (defined by PRO2), and incomplete or loss of response to SC VDZ 108mg EOW when the drug was intensified.

View Article and Find Full Text PDF

Background: The brain-gut-microbiome (BGM) axis is a communication network through which the brain and gastrointestinal microbiota interact via neural, hormonal, immune, and gene expression mechanisms. Gut microbiota dysbiosis is thought to contribute to neurocognitive disorders, including perioperative neurocognitive disorder (PND), and to various metabolic abnormalities. Recently, we reported that sevoflurane induces neurocognitive deficits in exposed rats as well as their future offspring, with male offspring being particularly affected (intergenerational PND).

View Article and Find Full Text PDF

From Gut Inflammation to Cardiovascular Conflagration: Mapping IBD's Cardiometabolic Risks.

Curr Atheroscler Rep

September 2025

Division of Gastroenterology and Hepatology, Lynda K. and David M. Underwood Center for Digestive Health, Houston Methodist Hospital, Houston, TX, USA.

Purpose Of Review: This review aims to characterize the known cardiovascular (CV) manifestations associated with inflammatory bowel disease (IBD) and the underlying mechanisms driving these associations.

Recent Findings: Gut dysbiosis, a hallmark of patients with IBD, can result in both local and systemic inflammation, thereby potentially increasing the risk of cardiovascular disease (CVD) in the IBD population. Micronutrient deficiencies, anemia, and sarcopenia independently increase the risk of CVD and are frequent comorbidities of patients with IBD.

View Article and Find Full Text PDF